FI963571L - Method for treating conditions associated with the 5HT2B receptor - Google Patents
Method for treating conditions associated with the 5HT2B receptor Download PDFInfo
- Publication number
- FI963571L FI963571L FI963571A FI963571A FI963571L FI 963571 L FI963571 L FI 963571L FI 963571 A FI963571 A FI 963571A FI 963571 A FI963571 A FI 963571A FI 963571 L FI963571 L FI 963571L
- Authority
- FI
- Finland
- Prior art keywords
- conditions associated
- treating conditions
- 5ht2b receptor
- 5ht2b
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Liquid Crystal Substances (AREA)
- Investigation Of Foundation Soil And Reinforcement Of Foundation Soil By Compacting Or Drainage (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21262294A | 1994-03-11 | 1994-03-11 | |
| US08/380,566 US5688807A (en) | 1994-03-11 | 1995-02-06 | Method for treating 5HT2B receptor related conditions |
| US08/380,565 US5663178A (en) | 1995-02-06 | 1995-02-06 | Tetrahydro-beta carbolines |
| PCT/US1995/003099 WO1995024200A1 (en) | 1994-03-11 | 1995-03-10 | Method for treating 5ht2b receptor related conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI963571A0 FI963571A0 (en) | 1996-09-10 |
| FI963571A7 FI963571A7 (en) | 1996-11-08 |
| FI963571L true FI963571L (en) | 1996-11-08 |
Family
ID=27395770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI963571A FI963571L (en) | 1994-03-11 | 1995-03-10 | Method for treating conditions associated with the 5HT2B receptor |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0749313A4 (en) |
| JP (1) | JPH09510216A (en) |
| CN (1) | CN1148340A (en) |
| AU (1) | AU679635B2 (en) |
| CA (1) | CA2185236A1 (en) |
| CZ (1) | CZ264996A3 (en) |
| FI (1) | FI963571L (en) |
| HU (1) | HUT75522A (en) |
| IL (1) | IL112958A0 (en) |
| NO (1) | NO963785L (en) |
| WO (1) | WO1995024200A1 (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457101A (en) * | 1994-06-03 | 1995-10-10 | Eli Lilly And Company | Thieno[1,5]benzoidiazepine use |
| CA2218143A1 (en) * | 1995-04-18 | 1996-10-24 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-ht7 receptor |
| GB9523999D0 (en) | 1995-11-23 | 1996-01-24 | Lilly Co Eli | Indolyl neuropeptide y receptor antagonists |
| BR9708146A (en) * | 1996-03-15 | 1999-07-27 | Lilly Co Eli | Treatment process for common cold or allergic rhinitis |
| US5880134A (en) * | 1996-03-20 | 1999-03-09 | Eli Lilly And Company | Method for using ergoline compounds to effect physiological and pathological functions at the 5-HT7 receptor |
| IL126063A (en) * | 1996-03-25 | 2002-04-21 | Lilly Co Eli | Pharmaceutical compositions containing olanzapine for treating migraine pain |
| US5886003A (en) * | 1996-03-25 | 1999-03-23 | Eli Lilly And Company | Methods of treating or ameliorating the symptoms of venomous bites and stings |
| EP0942722B1 (en) * | 1996-03-25 | 2004-05-19 | Eli Lilly And Company | Tetrahydro-beta-carboline compounds |
| WO2000069437A1 (en) | 1999-05-18 | 2000-11-23 | Synaptic Pharmaceutical Corporation | Use of agonists or antagonists of the 5-ht7 receptor to treat disorders of the bladder |
| DK1188747T3 (en) | 1999-05-24 | 2006-01-23 | Mitsubishi Pharma Corp | Phenoxypropylamine compounds |
| US6444477B1 (en) * | 2000-11-28 | 2002-09-03 | Pharmagene Laboratories Limited | Assay method for detecting 5-HT2B antagonists |
| GB0203412D0 (en) | 2002-02-13 | 2002-04-03 | Pharmagene Lab Ltd | 5-HT 2B receptor antagonists |
| DE602004016491D1 (en) * | 2003-05-09 | 2008-10-23 | Esteve Labor Dr | USE OF SULPHONAMIDE DERIVATIVES FOR THE PREPARATION OF A MEDICAMENT FOR PREVENTING OR TREATING SCREENING |
| JP4998258B2 (en) * | 2005-02-08 | 2012-08-15 | アステラス製薬株式会社 | Drugs for irritable bowel syndrome |
| EP1923387B1 (en) | 2005-08-08 | 2011-10-19 | Astellas Pharma Inc. | Acylguanidine derivative or salt thereof |
| JP5157893B2 (en) * | 2006-02-20 | 2013-03-06 | アステラス製薬株式会社 | Pyrrole derivative or its salt |
| US8338447B2 (en) | 2008-03-24 | 2012-12-25 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| WO2010058858A1 (en) | 2008-11-21 | 2010-05-27 | ラクオリア創薬株式会社 | Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity |
| TW201038569A (en) * | 2009-02-16 | 2010-11-01 | Abbott Gmbh & Co Kg | Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy |
| US20130137705A1 (en) * | 2009-09-23 | 2013-05-30 | Sarvajit Chakravarty | Pyrido[3,4-b]indoles and methods of use |
| US9079904B2 (en) | 2009-09-23 | 2015-07-14 | Medivation Technologies, Inc. | Pyrido[3,4-B]indoles and methods of use |
| IL295050A (en) | 2016-04-01 | 2022-09-01 | Recurium Ip Holdings Llc | Estrogen receptor modulators |
| EP3519816A4 (en) | 2016-09-29 | 2020-05-06 | The Regents of the University of California | CONNECTIONS FOR INCREASING NEURONAL PLASTICITY |
| BR112021016650A2 (en) * | 2019-02-27 | 2021-11-03 | Univ California | n-Substituted Indoles and Other Heterocycles for Treating Brain Disorders |
| CN113784962B (en) | 2019-02-27 | 2025-04-25 | 加利福尼亚大学董事会 | Azacyclohepta-indoles and other heterocyclic compounds for the treatment of brain disorders |
| CA3148221A1 (en) | 2019-08-06 | 2021-02-11 | Recurium Ip Holdings, Llc | Estrogen receptor modulators for treating mutants |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| AU2021337466A1 (en) * | 2020-09-01 | 2023-03-30 | Enveric Biosciences Canada Inc. | Halogenated psilocybin derivatives and methods of using |
| CA3229044A1 (en) | 2021-08-12 | 2023-02-16 | Kuleon Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| JP2025502615A (en) | 2021-12-15 | 2025-01-28 | デリックス セラピューティクス,インク. | Phenoxy and benzyloxy substituted psychoplastogens and uses thereof |
| WO2023143393A1 (en) * | 2022-01-29 | 2023-08-03 | 上海科技大学 | Tricyclic compound, and preparation method therefor and use thereof |
| WO2025137581A1 (en) * | 2023-12-21 | 2025-06-26 | Atai Therapeutics, Inc. | Novel tetrahydro pyridine substituted indole and azaindoles, compositions of matter and pharmaceutical compositions |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3492304A (en) * | 1968-06-24 | 1970-01-27 | Warner Lambert Pharmaceutical | 5,6,7,7a,8,8a,9,10,12,12a-decahydro-11h-benz(b)indolo(3,2,1-ij) 1,5 naphthyridin-11-ones |
| DE3240514A1 (en) * | 1982-10-29 | 1984-05-03 | Schering AG, 1000 Berlin und 4709 Bergkamen | SS-CARBOLINE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME |
| US4520024A (en) * | 1983-02-11 | 1985-05-28 | Eli Lilly And Company | Method of selectively blocking peripheral vascular serotonergic receptors |
| US5300645A (en) * | 1993-04-14 | 1994-04-05 | Eli Lilly And Company | Tetrahydro-pyrido-indole |
| EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
-
1995
- 1995-03-10 EP EP95914014A patent/EP0749313A4/en not_active Withdrawn
- 1995-03-10 CA CA002185236A patent/CA2185236A1/en not_active Abandoned
- 1995-03-10 FI FI963571A patent/FI963571L/en unknown
- 1995-03-10 CN CN95193029A patent/CN1148340A/en active Pending
- 1995-03-10 IL IL11295895A patent/IL112958A0/en unknown
- 1995-03-10 CZ CZ962649A patent/CZ264996A3/en unknown
- 1995-03-10 JP JP7523692A patent/JPH09510216A/en active Pending
- 1995-03-10 HU HU9602482A patent/HUT75522A/en unknown
- 1995-03-10 WO PCT/US1995/003099 patent/WO1995024200A1/en not_active Ceased
- 1995-03-10 AU AU21186/95A patent/AU679635B2/en not_active Ceased
-
1996
- 1996-09-10 NO NO963785A patent/NO963785L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0749313A1 (en) | 1996-12-27 |
| NO963785L (en) | 1996-11-01 |
| EP0749313A4 (en) | 2001-10-24 |
| IL112958A0 (en) | 1995-06-29 |
| FI963571A7 (en) | 1996-11-08 |
| AU679635B2 (en) | 1997-07-03 |
| NO963785D0 (en) | 1996-09-10 |
| WO1995024200A1 (en) | 1995-09-14 |
| HUT75522A (en) | 1997-05-28 |
| CN1148340A (en) | 1997-04-23 |
| HU9602482D0 (en) | 1996-11-28 |
| AU2118695A (en) | 1995-09-25 |
| CZ264996A3 (en) | 1998-01-14 |
| CA2185236A1 (en) | 1995-09-14 |
| FI963571A0 (en) | 1996-09-10 |
| JPH09510216A (en) | 1997-10-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI963571L (en) | Method for treating conditions associated with the 5HT2B receptor | |
| FI954863A0 (en) | Improved method for forming polymers | |
| FI940487L (en) | Troubleshooting method for the development process | |
| DE69534965D1 (en) | deposition method | |
| FI953209A7 (en) | Method for reaching the invited subscriber | |
| FI972318A0 (en) | Method for removing the window | |
| FI962069L (en) | Method for preparing carpolactam | |
| FI971568A7 (en) | Method for treating resistant tumors | |
| EP0669362A3 (en) | Method for the preparation of organic solvent-soluble polytitanosiloxanes. | |
| DE69520558D1 (en) | HALOGENING PROCESS | |
| KR970001365A (en) | Method for preparing alkylhydrogenchlorosilane | |
| FI20050181L (en) | Method for preparing 21-chlorocorticosteroids | |
| ZA952022B (en) | Method for treating 5HT2B receptor related conditions | |
| DE69703305D1 (en) | SYSTEM FOR PRODUCING UPHOLSTERY ELEMENTS | |
| FI952576L (en) | Tank | |
| FI955800L (en) | Method for preparing aminoalkylguanidines | |
| FI944583L (en) | Method for starting the elevator | |
| FI964001L (en) | Method for preparing 7-trialkylsilylbaccatin III | |
| DE69507032D1 (en) | CHLORHYDRINE PROCESS | |
| EP0669428A3 (en) | Method for laying roads. | |
| FI963018L (en) | Method for preparing gammapyrones | |
| DE69321644D1 (en) | Improvements for heaters | |
| FI971675L (en) | Method for inhibiting bradykinin-related conditions | |
| FI964002A7 (en) | Process for preparing 7-hydroxytaxanes | |
| FI955856A0 (en) | Method for decarbonylating sugars |